Theratechnologies Forecasts Fiscal Year 2024 Sales Of $87M-$90M Versus Consensus Of $92.85M, With Adjusted EBITDA Of $13M-$15M
Portfolio Pulse from Benzinga Newsdesk
Theratechnologies forecasts its fiscal year 2024 sales to be between $87M-$90M, which is below the consensus estimate of $92.85M. The company also expects adjusted EBITDA to be between $13M-$15M.
February 21, 2024 | 12:38 pm
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
Theratechnologies forecasts lower-than-expected sales for FY2024 at $87M-$90M vs. consensus of $92.85M, with adjusted EBITDA of $13M-$15M.
The forecasted sales being below the consensus estimate suggests potential challenges in revenue growth or market conditions that could negatively impact investor sentiment and the stock price in the short term.
CONFIDENCE 85
IMPORTANCE 90
RELEVANCE 100